Texas Biotech (TXB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Texas Biotech (TXB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NVestor who wrote (78)	3/2/1997 5:40:00 PM
From: scaram(o)uche	of 834

NVestor....... The trial is being run in patients who are "allergic" to heparin (heparin-induced thrombocytopenia). If FDA approves the product, Novastan (argatroban) will only receive labeling for the indication for which it was tested. The liability would certainly be greater for the physician that used it off-label than for the physician that used heparin in a patient with no known "allergy". Your thought sounds good ($$) to me, but it won't happen much, if at all, my best guess........ even apart from cost control issues. Sounds like you should watch and listen a bit more before investing in biotech. :-) Rick

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next